Company Overview and News

Valeant Pharmaceuticals Can Still Go Higher - Cramer's Lightning Round (5/21/18)

2018-05-22 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, May 21.

Walgreens Boots Alliance And AmerisourceBergen: Which Is The Better Investment?

2018-05-21 seekingalpha
Each week I run a scan for stocks that have a strong dividend growth record and that are considered oversold on a technical basis. Walgreens Boots Alliance (WBA) was a company that was identified in that weekly scan. This article will look at WBA's balance sheet, investment opportunity, and the risks of investing in WBA. This article will also consider AmerisourceBergen Corp. (ABC) as well. At current prices I don't think an investment in WBA is suitable for me.

Spotlight On Gambling Reset And Banking Bill

2018-05-19 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

Top Gainers in the Consumer Sector Last Week

2018-05-15 marketrealist
TripAdvisor (TRIP) reported its first-quarter results on May 10. Its revenue grew 1.6% to $378 million and surpassed the consensus estimate by 4.6%. It reported a drastic increase in earnings to $0.30 per share compared to EPS (earnings per share) of $0.24 in the first quarter of 2017. Its EPS also surpassed the consensus estimate of $0.16 per share. The stock rose 24.2% last week.

The 10 Best Dividend Aristocrat Stocks Today

2018-05-15 valuewalk
At Sure Dividend, we make no secret of the fact that we are huge proponents of investing in high-quality dividend growth stocks. Specifically, we suggest investors looking for the best dividend growth stocks take a hard look at the Dividend Aristocrats.

Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?

2018-05-15 zacks
President Donald Trump on Friday unveiled his plans of lowering drug prices, in keeping with promises he made in the run-up to the Presidential elections. Pharmaceutical companies and the broader industry had been anticipating that Trump would come down heavily on them, as he had long criticized drugmakers of “getting away with murder” by charging way too much for their products.

Show Me The Money

2018-05-11 seekingalpha
STORE Capital only invests in profit center real estate, which means that profitable locations are highly likely to be among the most senior obligations of its tenant base.

Earnings Show CVS Health Corp on Track To Benefit From Transformation | InvestorPlace

2018-05-11 investorplace
CVS Health Corp (NYSE:CVS) reported Q1 earnings, the shares are back to where they started, despite a bit of a roller-coaster ride. But what are investors to make of CVS stock after April’s 12% gain?

Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up

2018-05-08 zacks
Fred’s Inc. confirmed sale of certain assets of its specialty pharmacy business, EntrustRx, to CVS Health Corporation (CVS - Free Report) . The company has been considering the divesture of its specialty pharmacy unit for a while, in a bid to monetize non-core assets, reduce debt load and induce a turnaround in its operations. Per the terms, Fred’s is entitled to receive $40 million along with a sum equivalent to EntrustRx’s inventory value.

Drugstore Stocks Tumble ahead of Trump’s New Drug Policy

2018-05-08 marketrealist
The stocks of top drugstore chains CVS Health (CVS) and Walgreens Boots Alliance (WBA) were down yesterday amid ongoing tensions regarding a policy change in US drug pricing. Walgreens and CVS fell 2.3% and 2.1%, respectively, yesterday. The two companies lost 6.1% and 11.6% in the first week of May. However, a large part of the decline in CVS Health’s price is also due to its recent top-line miss.

Merck Is Inexpensive - Cramer's Lightning Round (5/7/18)

2018-05-08 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, May 7.

Price Is What You Pay, Value Is What You Get

2018-05-07 seekingalpha
The reduced overhang and increased liquidity has given Ladder substantially more shelf space and investor appeal.

Here Are 52 Top NASDAQ Stocks By Yield, Upside And Gains For May

2018-05-07 seekingalpha
"The Nasdaq-100 Index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization." 52 pay dividends.

It Sucks To Be A Grownup

2018-05-06 seekingalpha
This past week saw a slew of earnings and more evidence that the Four are increasing their influence, and have become toxic for our economy and the commonwealth.

Anthem Inc Is Boring, But Profitable

2018-05-04 investorplace
When it comes to value investing, sometimes boring is good. Anthem Inc (NYSE:ANTM) is a good case study of a company that does not get much attention but is doing well for investors. And last week’s first-quarter results strengthen that view.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 931427108